{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:12Z","timestamp":1781697372943,"version":"3.54.5"},"reference-count":21,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Global randomized controlled trials (RCTs) are used to inform reimbursement decisions in multiple markets, meaning the transportability of findings from these RCTs to multiple country-specific populations is critical for evidence-based decision making. This study evaluated the transportability of the FINEARTS-HF trial, which assessed finerenone in patients with heart failure (HF) and left ventricular ejection fraction \u226540%, to a real-world US population.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A three-phase transportability assessment was conducted. First, potential effect modifiers were identified through systematic literature review and confirmed through interaction analyses using data from FINEARTS-HF. Second, representativeness was assessed by comparing the distribution of effect modifiers in the trial and a population derived from a US electronic health record dataset. Third, direct proxy tests explored heterogeneity of treatment effects in FINEARTS-HF between US and non-US patients.\n                    <jats:bold>Results:<\/jats:bold>\n                    Effect modifier analysis identified that treatment effects of finerenone were homogeneous across subgroups, with limited evidence of effect modification. Comparisons with the US target population indicated overall good alignment across key characteristics, with only modest imbalances, suggesting that the trial results may underestimate positive treatment effects in the US target population (i.e., effect on the primary outcome over 0.84 [0.74; 0.95]). Direct proxy tests found no statistically significant regional heterogeneity in treatment effects.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study provides a structured assessment of finerenone trial transportability. Findings support the robustness of FINEARTS-HF results for US clinical practice and are not impacted by the prevalence of SGLT2-is use. The risk of transportability bias is likely to be low.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0003","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:18:26Z","timestamp":1778077106000},"source":"Crossref","is-referenced-by-count":0,"title":["Transportability of the comparative effect of finerenone for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction of \u226540%: insights from the FINEARTS-HF trial"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4139-941X","authenticated-orcid":false,"given":"Alex J","family":"Turner","sequence":"first","affiliation":[{"name":"Health Organisation, Policy &amp; Economics (HOPE), School of Health Sciences, University of Manchester, Manchester, M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-2537","authenticated-orcid":false,"given":"Claire","family":"Leboucher","sequence":"additional","affiliation":[{"name":"Putnam, 207 rue de Bercy, Paris, France"},{"name":"CEReSS-Health Services Research &amp; Quality of Life Center, Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Remuzat","sequence":"additional","affiliation":[{"name":"Putnam, 207 rue de Bercy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yik Ming","family":"Fung","sequence":"additional","affiliation":[{"name":"Bayer AG, Real-World Data Science &amp; AI, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pessina","sequence":"additional","affiliation":[{"name":"Bayer AG, Real World Evidence Center of Excellence, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Folkerts","sequence":"additional","affiliation":[{"name":"Bayer AG, HEOR &amp; HTA, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","unstructured":"National Institute for Health and Care Excellence. NICE real-world evidence framework. (2022). https:\/\/www.nice.org.uk\/corporate\/ecd9"},{"key":"e_1_3_8_4_2","unstructured":"Institute for Quality and Efficiency in Health Care. General methods. (2020). https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_v8-0.pdf"},{"issue":"4","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies","volume":"20","author":"Makady A","year":"2017","unstructured":"Makady A, Ham RT, de Boer A Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health 20(4), 520\u2013532 (2017).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/aje\/kwx164","article-title":"Transportability of trial results using inverse odds of sampling weights","volume":"186","author":"Westreich D","year":"2017","unstructured":"Westreich D, Edwards JK, Lesko CR Transportability of trial results using inverse odds of sampling weights. Am. J. Epidemiol. 186(8), 1010\u20131014 (2017).","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell PM","year":"2006","unstructured":"Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLOS Clin. Trials 1(1), e9 (2006).","journal-title":"PLOS Clin. Trials"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01323-1"},{"issue":"14","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/sim.8426","article-title":"Extending inferences from a randomized trial to a new target population","volume":"39","author":"Dahabreh IJ","year":"2020","unstructured":"Dahabreh IJ, Robertson SE, Steingrimsson JA Extending inferences from a randomized trial to a new target population. Stat. Med. 39(14), 1999\u20132014 (2020).","journal-title":"Stat. Med."},{"issue":"1","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-statistics-042522-103837","article-title":"A review of generalizability and transportability","volume":"10","author":"Degtiar I","year":"2023","unstructured":"Degtiar I, Rose S. A review of generalizability and transportability. Annu. Rev. Stat. Appl. 10(1), 501\u2013524 (2023).","journal-title":"Annu. Rev. Stat. Appl."},{"issue":"4","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report","volume":"12","author":"Drummond M","year":"2009","unstructured":"Drummond M, Barbieri M, Cook J Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12(4), 409\u2013418 (2009).","journal-title":"Value Health"},{"key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/CEOR.S14404","article-title":"Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application","volume":"3","author":"Goeree R","year":"2011","unstructured":"Goeree R, He J, O'Reilly D. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clin. Outcomes Res. 3, 89\u2013104 (2011).","journal-title":"Clin. Outcomes Res."},{"issue":"5","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/EDE.0000000000001633","article-title":"An overview of current methods for real-world applications to generalize or transport clinical trial findings to target populations of interest","volume":"34","author":"Ling AY","year":"2023","unstructured":"Ling AY, Montez-Rath ME, Carita P. An overview of current methods for real-world applications to generalize or transport clinical trial findings to target populations of interest. Epidemiology 34(5), 627\u2013636 (2023).","journal-title":"Epidemiology"},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1214\/14-STS486","article-title":"External validity: from do-calculus to transportability across populations","volume":"29","author":"Pearl J","year":"2014","unstructured":"Pearl J, Bareinboim E. External validity: from do-calculus to transportability across populations. Stat. Sci. 29(4), 579\u2013595 (2014).","journal-title":"Stat. Sci."},{"issue":"3","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11121-014-0513-z","article-title":"Assessing the generalizability of randomized trial results to target populations","volume":"16","author":"Stuart EA","year":"2015","unstructured":"Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev. Sci. 16(3), 475\u2013485 (2015).","journal-title":"Prev. Sci."},{"key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"1073678","DOI":"10.3389\/fmed.2022.1073678","article-title":"Transferability of real-world data across borders for regulatory and health technology assessment decision-making","volume":"9","author":"Jaksa A","year":"2022","unstructured":"Jaksa A, Arena PJ, Chan KKW Transferability of real-world data across borders for regulatory and health technology assessment decision-making. Front. Med. (Lausanne) 9, 1073678 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0064"},{"key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annepidem.2025.03.001","article-title":"Systematic review of applied transportability and generalizability analyses: a landscape analysis","volume":"104","author":"Vuong Q","year":"2025","unstructured":"Vuong Q, Metcalfe RK, Ling A Systematic review of applied transportability and generalizability analyses: a landscape analysis. Ann. Epidemiol. 104, 61\u201370 (2025).","journal-title":"Ann. Epidemiol."},{"issue":"16","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon SD","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391(16), 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_20_2","volume-title":"Heart Failure Society of America","author":"Lam CSP","year":"2025","unstructured":"Lam CSP, Fonarow GS, Fung YM Guideline-directed medical therapy treatment patterns in patients with newly diagnosed heart failure stratified by left ventricular ejection fraction in the United States. Presented at: Heart Failure Society of America. (26\u201329 September 2025)."},{"key":"e_1_3_8_21_2","volume-title":"Heart Failure Society of America","author":"Lam CSP","year":"2025","unstructured":"Lam CSP, Fonarow GS, Fung YM Clinical outcomes after onset of heart failure with left ventricular ejection fraction in the US. Presented at: Heart Failure Society of America. (26\u201329 September 2025)."},{"issue":"18","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 81(18), 1835\u20131878 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_8_23_2","unstructured":"Cochrane. Cochrane Handbook for Systematic Reviews of Interventions. (2024). https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:21:19Z","timestamp":1781695279000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2026-0003"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0003","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e260003"}}